Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayvon Modjarrad

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2021
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityM Gordon Joyce, Wei-Hung Chen, Rajeshwer S Sankhala, et al.
Biorxiv : the Preprint Server for Biology|June 23, 2021
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamstersKathryn McGuckin Wuertz, Erica K Barkei, Wei-Hung Chen, et al.
NPJ Vaccines|October 29, 2021
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challengeKathryn McGuckin Wuertz, Erica K Barkei, Wei-Hung Chen, et al.
Nature Medicine|February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Nature Communications|January 3, 2024
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaquesRajeshwer S Sankhala, Kerri G Lal, Jaime L Jensen, et al.
Cell Reports|December 17, 2021
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityM Gordon Joyce, Wei-Hung Chen, Rajeshwer S Sankhala, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2021
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityM Gordon Joyce, Wei-Hung Chen, Rajeshwer S Sankhala, et al.
Biorxiv : the Preprint Server for Biology|June 23, 2021
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamstersKathryn McGuckin Wuertz, Erica K Barkei, Wei-Hung Chen, et al.
NPJ Vaccines|October 29, 2021
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challengeKathryn McGuckin Wuertz, Erica K Barkei, Wei-Hung Chen, et al.
Nature Medicine|February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Nature Communications|January 3, 2024
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaquesRajeshwer S Sankhala, Kerri G Lal, Jaime L Jensen, et al.
Cell Reports|December 17, 2021
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityM Gordon Joyce, Wei-Hung Chen, Rajeshwer S Sankhala, et al.
Pageof 14